Sevara Mirakhmedova

Dr. Sevara Mirakhmedova

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SMSevara Mirakhmedova
Sevara Mirakhmedova
AAAmirkhan Amirkhanov
Amirkhan Amirkhanov
ESEvgenii Seliverstov
Evgenii Seliverstov
OEOksana Efremova
Oksana Efremova
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Background: There are no data on the daily regimen of compression therapy in patients with chronic venous disease. This systematic review aimed to establish the optimal daily duration of compression treatment. Methods: A systematic search of CENTRAL and MEDLINE was performed to identify RCTs, non-RCTs, reviews, systematic reviews, meta-analyses, and guidelines evaluating the use of compression regimens in the treatment of varicose veins. Results: Thirty-two RCTs, three non-RCTs, four observational studies, and two crossover trials reporting the duration and regimes of compression treatment fulfilled the inclusion criteria. The daily duration of compression was reported in patients after invasive treatment, for venous ulcer treatment, in patients with venous symptoms. The quality of the studies varied. We could not conduct a meta-analysis due to the heterogeneity of the research data and their quality. Twenty-three studies reported results of compression usage after invasive procedures. Eight studies reported daily duration regimens in patients with venous ulcers. Nine studies reported the impact of compression on venous symptoms and/or edema or limb volume change. One study was conducted to assess if compression improves QoL in venous patients. While there was a clear difference found in the daily duration depending on the clinical scenario, no data in support of exact regimens were found. Conclusions: There are no reliable data supporting exact daily regimens of compression treatment in various cohorts of CVD patients.

17 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAlvina Khachatryan
Alvina Khachatryan
DRDenis Rylnikov
Denis Rylnikov
SMSevara Mirakhmedova
Sevara Mirakhmedova
ESEvgeny I. Seliverstov
Evgeny I. Seliverstov
EAEvgeny S. An
Evgeny S. An
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Background: Pulmonary embolism (PE) patients are generally admitted to the hospital, which leads to significant burden on healthcare systems. Many PE patients are hemodynamically stable and can be ambulated safely. Direct oral anticoagulants (DOACs) do not need routine laboratory monitoring, which makes them a convenient option for outpatient care. Data on the outpatient management of PE patients using DOACs are scarce. Methods: We conducted a systematic search of MECENTRAL databases to identify randomized controlled trials (RCTs), non-randomized studies (non-RCTs), retrospective studies, reviews, systematic reviews, meta-analyses, and clinical guidelines evaluating the use of DOACs for outpatient treatment of PE patients. Results: A total of 833 publications were identified, and eight studies—two RCTs and six non-RCTs (two retrospective and four prospective)—were finally included. These studies reported rates of bleeding events, recurrent venous thromboembolism (VTE), PE-related mortality, and all-cause mortality among outpatients who received DOACs. No PE-related deaths were reported in any of the included studies. Bleeding events were reported in five studies, and recurrent VTE rates were reported in two studies. Study findings showed that the sPESI score has some disadvantages in selecting patients for home treatment. The quality of the studies varied considerably. A meta-analysis could not be performed due to heterogeneity in the study designs, patient populations, and outcome reporting. While the treatment results favored outpatient management of selected PE patients, no robust conclusions could be drawn from the published data. Conclusions: Outpatient treatment of PE with DOACs has some potential as an approach for managing selected patients. Hestia, POMPE-C and RESI scores are preferable for selecting PE patients for home treatment, but utilizing sPESI as the only tool has to be avoided. Apixaban and rivaroxaban are both safe, with a low bleeding risk. Large-scale prospective studies are required to establish the efficacy and safety of outpatient PE management using DOACs.

6 June 2025 in Journal of Venous Disorders
Verified
Journal Article
Closed access
SMSevara Mirakhmedova
Sevara Mirakhmedova
ESE.I. Seliverstov
E.I. Seliverstov
OGO.V. Golovanova
O.V. Golovanova
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Elastic compression is common in patients with chronic venous disease (CVD), but compliance with treatment is often low. Objective. To compare objective monitoring of patients’ compliance with compression treatment with self-reporting by patients diaries. Material and methods. Patients aged ≥18 years with C0S—C4S CVD were included. All participants were prescribed to wear class 1 compression knee-length stockings. We assessed subjectively measured and actual time of wearing of compression stocking. Data were collected using a diary of intraday wearing time filled in by the patient and thermograph fixed to the stocking cuff. Results. The study included 10 participants (7 women and 3 men). Mean age was 49±11 years (range 40—70). Participants were distributed as follows: class C1 — 1 (10%), C2 — 4 (40%), C3 — 5 patients (50%). Seven patients (70%) were recommended to use compression for 6—8 hours daily, 3 patients (30%) — for 10—12 hours daily. Only 5 (50%) patients wore the hosiery for 7 days, while three patients missed some days as evidenced by thermograph and diary. Two patients (20%) reported daily use of hosiery, but thermography data indicated wearing for only 4 days in one case and 1 day in another case. The number of missed days registered by thermograph was 16, while patients reported only 7 days (p=0.066). Eight participants (80%) overstated total weekly wearing time. None participant reported any discomfort associated with thermograph or any adverse events related to wearing the compression hosiery. Conclusion. The use of a compact logger to measure ambient temperature provides a more accurate assessment of the compression hosiery wearing duration. Patients’self-reporting of compression wearing duration is associated with a risk of inaccurate data regarding compliance with compression treatment.

27 December 2025 in Journal of Venous Disorders
Verified
Journal Article
Closed access
SMSevara Mirakhmedova
Sevara Mirakhmedova
ESE.I. Seliverstov
E.I. Seliverstov
OGO.V. Golovanova
O.V. Golovanova
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Elastic compression is common in patients with chronic venous diseases (CVD). The evidence regarding the efficacy of compression treatment in reducing subjective symptoms of CVD is inconsistent. Objective — of the study was to identify factors influencing the efficacy of compression therapy in reducing subjective symptoms of CVD. Material and methods. The study included patients with CVD classified as C0S—C3S according to the CEAP. All patients wore first-class compression below-knee stockings (RAL standard). Changes in venous pain and discomfort in the lower limbs were assessed using the Visual Analog Scale (VAS) before and four weeks after treatment initiation. Potential influencing factors included age, sex, BMI, clinical class according to CEAP, and daily duration of compression wear. Multiple linear regression analysis was performed to evaluate their impact. Results. The study involved 49 patients with symptomatic CVD, with a mean age of 44.3±10.5 years, the average BMI was 26.1±3.4. Distribution across CEAP classes was as follows: C0 — 1 (2%), C1 — 20 (41%), C2 — 13 (26%), C3 — 15 (31%). No factors showed a significant correlation with changes in venous pain severity (p>0.05). A trend was observed toward an association between daily wear duration and changes in lower limb discomfort (p=0.07). Female sex was associated with a more intensive reduction in pain severity (p=0.04). Longer wear duration of the compression below-knee stockings was linked to a more significant decrease in pain and discomfort in the lower limbs (p=0.07 and p=0.04, respectively). Conclusions. Female sex and a 12-hour daily wear regimen are predictors of a more noticeable effect on venous pain. The only predictor of a more significant reduction in discomfort related to CVD is a 12-hour therapy regimen.

27 September 2020 in Тромбоз, гемостаз и реология
Verified
Journal Article
Closed access
АААида Набиевна Атаева
Аида Набиевна Атаева
SMSevara Mirakhmedova
Sevara Mirakhmedova
ВЯВ.ю. Яроцкая
В.ю. Яроцкая
Гемофилии — заболевания, вызванные единичными мутациями в генах и проявляющиеся дефицитом белков, участвующих в каскадах свертывания крови. Характеризуются приобретённой тенденцией к кровотечениям на протяжении всей жизни и представляют собой потенциально жизнеугрожающее состояние. Важно вовремя диагностировать данную патологию крови и своевременно начать профилактику, чтобы избежать возможных осложнений и эпизодов сильных кровотечений. Стандартом на сегодняшний день является заместительная терапия недостающих факторов свертывания, исследуются способы увеличения периодов полураспада и меры предупреждения развития аутоантител — внедряются подкожные формы введения препаратов. Однако сегодня профилактика и лечение гемофилии — это не только заместительная терапия недостающих факторов свертывания. В разработках и на разных стадиях клинических исследований находятся потенциальные мишени для опосредованного восполнения недостающих факторов свертывания. Основная цель в лечении гемофилий — профилактика кровотечений, но при неадекватной терапии, потере ее эффективности или отсутствии своевременной диагностики развившееся кровотечение представляет собой угрозу для жизни пациентов и требует специфического подхода. Hemophilia is a disease caused by single gene mutation and is manifested by a defi ciency of proteins involved in blood coagulation cascades. This disease is characterized by an acquired tendency to bleed throughout life and represents a potentially life-threatening condition. It is important to recognize this condition early and start the prevention in time to avoid possible complications and episodes of severe bleeding. The standard therapy today is replacement for coagulation factors; methods of increasing the half-life and prevention of the development of autoantibodies are being studied — subcutaneous forms of drug administration are being introduced. However, today the prevention and treatment of hemophilia is not only replacement therapy of coagulation factors. Potential targets for mediated replacement of missing coagulation factors are in development and at various stages of clinical research. The main goal in the treatment of hemophilia is to prevent bleeding, but with inadequate therapy, loss of its effectiveness or lack of timely diagnosis, severe bleeding is a threat to the lives of patients, and requires a specific approach.

1 January 2021 in Journal of Venous Disorders
Verified
Journal Article
Closed access
IZI.A. Zolotukhin
I.A. Zolotukhin
EIE.A. Ilyukhin
E.A. Ilyukhin
SMSevara Mirakhmedova
Sevara Mirakhmedova
ISI.A. Suchkov
I.A. Suchkov
На сегодняшний день отсутствуют достоверные данные о заболеваемости варикозной болезнью и другими хроническими заболеваниями вен (ХЗВ). ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить заболеваемость, факторы риска и естественное развитие ХЗВ. МАТЕРИАЛ И МЕТОДЫ Проспективное наблюдательное когортное исследование заболеваемости и особенностей течения варикозной болезни и ХЗВ (англ. Prospective cohort study for VarIcose veiNs in CIdence and natural course — VINCI) является бессрочным и предназначено для долгосрочного наблюдения за отобранными пациентами с ХЗВ и без ХЗВ на момент включения. В число участников входят сами исследователи и их близкие родственники. Исследователями являются хирурги и сосудистые хирурги, которые регулярно ведут пациентов с ХЗВ. Пациенты с ХЗВ, по поводу которых предпринималось инвазивное лечение и с венозным тромбозом в анамнезе или на момент включения, в исследование участвовать не будут. Клиническое обследование и ультразвуковое исследование вен нижних конечностей будут проводиться ежегодно. Данные будут собираться и храниться в защищенном регистре Ассоциации флебологов России. Для оценки прогрессирования ХЗВ будут рассчитаны такие параметры, как заболеваемость, абсолютный и относительный риск. Личные данные исследуемых собираться и храниться не будут. РЕГИСТРАЦИЯ ИССЛЕДОВАНИЯ Исследование зарегистрировано на платформе ClinicalTrials.gov, идентификатор NCT04546750. Зарегистрировано 5 сентября 2020 г.